Clinical Trial Update: Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and efficacy of a ketotifen 4.0% patch compared with placebo, olopatadine solution, and artificial tears in an acute allergi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• Artificial Tears
• Ketotifen 4.0% patch (ketotifen)
• Olopatadine 0.2% Ophthalmic Solution (olopatadine hydrochloride)
• Placebo Patch

Snippet

Sponsor: Senju USA, Inc. | Conditions: Allergic Conjunctivitis | Phase 2 | Status: COMPLETED